Form 4: Elanco Animal Health CEO Acquires Deferred Stock Units
SEC Form 4 Filing
Jeffrey N. Simmons, CEO of Elanco Animal Health, reports acquisition of deferred stock units.
Summary
- On August 23, 2024, Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired 190.0645 deferred stock units.
- These deferred stock units represent the right to receive one share of Elanco common stock or the cash equivalent.
- The price of the underlying common stock was $14.57.
- Following the transaction, Simmons directly owns 3,123.8076 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.
Future Outlook
Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 08/23/2024 | Date of transaction: Acquisition of deferred stock units. |
| 08/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.